Provided by Tiger Fintech (Singapore) Pte. Ltd.

Baxter

29.80
-0.1200-0.40%
Post-market: 29.800.00000.00%19:57 EDT
Volume:3.51M
Turnover:104.86M
Market Cap:15.29B
PE:-27.19
High:30.10
Open:29.87
Low:29.54
Close:29.92
Loading ...

BUZZ-US medical device makers fall as China retaliates to US tariffs

Reuters
·
04 Apr

Baxter International Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
03 Apr

Evercore ISI Adjusts Baxter International Price Target to $45 From $44, Maintains Outperform Rating

MT Newswires Live
·
02 Apr

Baxter International Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
01 Apr

Baxter International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 Mar

Baxter International Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
26 Mar

Baxter International Inc. Stock Rises Monday, Still Underperforms Market

Dow Jones
·
25 Mar

Baxter International Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
20 Mar

Top Stock Reports for Visa, Johnson & Johnson & Thermo Fisher Scientific

Zacks
·
19 Mar

Baxter International Appoints New Leadership Amid Strategic Changes

TIPRANKS
·
14 Mar

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Business Wire
·
11 Mar

Baxter (BAX): Buy, Sell, or Hold Post Q4 Earnings?

StockStory
·
11 Mar

Baxter International Is Maintained at Overweight by Barclays

Dow Jones
·
10 Mar

Baxter price target raised to $41 from $39 at Barclays

TIPRANKS
·
10 Mar

Baxter International (BAX) Gets a Buy from Barclays

TIPRANKS
·
10 Mar

Baxter International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
08 Mar

Barclays Raises Baxter International Price Target to $41 From $39, Overweight Rating Maintained

MT Newswires Live
·
08 Mar

Baxter Stock Likely to Gain Following the Introduction of Voalte Linq

Zacks
·
06 Mar

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Business Wire
·
06 Mar

Baxter International Inc. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
06 Mar